South Korea · Delayed Price · Currency is KRW ALTEOGEN Company Description
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars.
The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology.
It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology; and ALT-LS2, a SC (subcutaneous) formulation of trastuzuamb for the treatment of breast and gastric cancer.
The company has a strategic alliance with Kissei Pharmaceutical for the development of ALT-L9, a biosimilar of Eylea (Aflibercept) which is currently under Phase 1 trial; Cristalia for the development of ALT-L2, a biosimilar of Herceptin (Trastuzumab), a monoclonal antibody for the treatment of breast cancer, which is in the Phase II clinical trial; and Biogen Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4.
ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.
| Country | South Korea |
| Founded | 2008 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 159 |
| CEO | Soon-Jae Park |
Contact Details
Address: 62, Yuseong-daero Daejeon, 34054 South Korea | |
| Phone | 82 4 2384 8780 |
| Website | alteogen.com |
Stock Details
| Ticker Symbol | 196170 |
| Exchange | KOSDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| ISIN Number | KR7196170005 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Soon-Jae Park | Chief Executive Officer |
| Hang Yeon Kim | Chief Financial Officer |